3 results
Approved WMOCompleted
Objective: to investigate if Ulipristal is non-inferior to GnRH in terms of intra-operative blood-loss (primary outcome), surgical time, surgical ease, complications, quality of life and costs.
Approved WMOPending
Primary Objective• To characterize preliminary targeting properties of [68Ga]-NeoBOMB1 in patients with malignancies known to overexpress GRPR.Secondary objectives• To assess safety and tolerability of a single diagnostic dose of [68Ga]-NeoBOMB1…
Approved WMOCompleted
To assess the proportion of patients who are alive without disease progression at 6 months based on local investigator assessment per RECIST v1.1 in cohort A and cohort B 13-03-2019: new cohort added (3 cohorts now)